🔎 Trials Near Me

Beranda › Sarkoma Jaringan Lunak › Massachusetts › Boston

Uji klinis Sarkoma Jaringan Lunak di Boston, MA

18 studi untuk Sarkoma Jaringan Lunak mencari peserta di lokasi sekitar Boston (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.

Teks studi resmi (Bahasa Inggris)

Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →

Distance-Based Exercise to Preserve Function and Prevent Disability

Menerima peserta
  • Dana-Farber Cancer Institute, Boston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT07059884

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

Menerima pesertaFase 2
  • Dana-Farber Cancer Institute - Oncology Department, Boston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT06760819

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

Menerima pesertaFase 1/2
  • Dana Farber Cancer Institute., Boston
Hingga usia 25 · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT04094610

Anti-GD2 ADC M3554 in Advanced Solid Tumors

Menerima pesertaFase 1
  • Dana-Farber Cancer Institute, Boston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT06641908

Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

Menerima pesertaFase 1/2
  • Massachusetts General Hospital, Boston
  • Dana Farber Cancer Institute, Boston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT05732831

First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors

Menerima pesertaFase 1
  • Dana-Farber Cancer Institute, Boston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 4 Sep 2026 · NCT06644755

Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma

Menerima pesertaFase 1
  • Dana-Farber Cancer Institute, Boston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 4 Sep 2026 · NCT05711615

Serial MRI Scans During Radiation Therapy

Menerima peserta
  • Brigham and Women Hospital, Boston
  • Dana Farber Cancer Institute, Boston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Sep 2026 · NCT04188535

Bridging Adolescent and Young Adult Sarcoma Survivors With Personalized Oncology Exercise Service (AYA-ONE): A Pilot Intervention

Menerima peserta
  • Boston Children's Hospital, Boston
  • Brigham and Women's Hospital, Boston
  • Dana-Farber Cancer Institute, Boston
Usia 15 hingga 39 · Semua jenis kelamin · Diperbarui 26 Agu 2026 · NCT07662239

STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas

Menerima pesertaFase 1/2
  • Dana Farber Cancer Institute, Boston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT06975293

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

Menerima pesertaFase 1/2
  • Dana Farber Cancer Institute, Boston
Hingga usia 30 · Semua jenis kelamin · Diperbarui 3 Agu 2026 · NCT06239272

Prospective Study Evaluating the Treatment Outcomes for Localised Recurrent, Resectable Retroperitoneal Liposarcoma

Menerima pesertaStudi observasional
  • Brigham and Women's Hospital, Boston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Jul 2026 · NCT07377747

Clonal Hematopoiesis Chemotherapy and Radiation Effects Study

Menerima pesertaStudi observasional
  • Dana-Farber Cancer Institute, Boston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Jun 2026 · NCT07675967

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Menerima pesertaFase 1/2
  • Massachusetts General Hospital,, Boston
Usia 12 ke atas · Semua jenis kelamin · Diperbarui 27 Mei 2026 · NCT03093116

Video Education With Result Dependent dIsclosure

Menerima peserta
  • Dana Farber Cancer Institute, Boston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Mei 2026 · NCT05225428

Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas

Menerima pesertaFase 1/2
  • Boston Children's Hospital, Boston
  • Dana-Farber Cancer Institute, Boston
  • Brigham and Women's Hospital, Boston
Usia 12 hingga 49 · Semua jenis kelamin · Diperbarui 19 Feb 2026 · NCT06709495

A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

Menerima pesertaFase 1/2
  • Massachusetts General Hospital, Boston
  • Dana Farber Cancer Institute, Boston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 8 Okt 2025 · NCT04370587

REtroperitoneal SArcoma Registry: an International Prospective Initiative

Menerima pesertaStudi observasional
  • Brigham and Women's Hospital/Dana-Farber Cancer Institute, Boston
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 12 Feb 2019 · NCT03838718

Uji klinis Sarkoma Jaringan Lunak di kota lain

Studi lain di Boston

Dari ClinicalTrials.gov, data diambil 3 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.